The Hereditary Disease study is to study the diagnosis, pathogenesis and pathogenesis of various genetic diseases, the development of prevention and treatment drugs, and clinical research. The localization and genetic analysis of polygenic genetic susceptibility genes is a new hotspot in genetic disease research in recent years. In addition, genetic disease gene therapy and the development of nucleic acid drugs are also hot issues in genetic disease research, such as genetic hATTR amyloidosis RNAi drugs. It has entered the FDA’s listing approval stage and will bring good news to the treatment of rare genetic diseases.
RiboBio provids oligonucleotide CDMO services and enable new drug discovery, manufacturing and to the market.